APYX

Business Context and Reporting Period

Company: Bovie Medical Corporation (Ticker: BVX)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2006
Business Overview: Bovie is a medical device manufacturer focused on electrosurgical generators, accessories, battery-operated cauteries, and endoscopic instruments. The company operates through three segments: Electrosurgical products, Cauteries, and Other products. It markets products globally under the Bovie/Aaron brand and via private label/OEM agreements.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 32% to $26.7 million, driven primarily by a 39% increase in domestic sales ($23.4M vs $16.8M). International sales declined slightly by 4%.
• Profitability Surge: Net income increased 561% to $2.7 million. Operating income jumped from $0.4 million to $2.6 million.
• Product Mix Shift: The "Other" product line (including development fees and new technologies) saw a 107% increase in sales. Electrosurgical sales grew 27%.
• Customer Concentration: Arthrex, Inc. accounted for 22% of total revenues (up from 15% in 2005), and Medtronic, Inc. accounted for 11% (up from 0% as a major customer in 2005).
• Cost Efficiency: Cost of sales as a percentage of revenue decreased from 62.6% to 60.3%, improving gross margins.
• Acquisitions: The company acquired assets from Lican Developments Ltd. (forming Bovie Canada) and Henvil Corp. Ltd., resulting in significant increases in intangible assets and fixed assets.

Guidance, Outlook, and Risks

Outlook and Management Commentary

Management anticipates that the acquisition of Lican Developments and the launch of new products (MEG forceps, ICON GI device, Bovie Button) will drive future revenue growth and higher operating margins. While short-term costs related to the Canada facility may impact the bottom line, the long-term outlook is positive with a focus on reducing reliance on OEM business and expanding into niche markets like gastroenterology.

Risks and Contingencies

• Customer Concentration: Heavy reliance on Arthrex (22%) and Medtronic (11%). Loss of these contracts would materially adversely affect the business.
• Regulatory Risk: Products are subject to FDA and international regulations. Delays in clearance for new products (e.g., ICON GI, Suture Removal Device) could impact revenue timelines.
• Intellectual Property: Potential litigation regarding J-Plasma technology with a third party (Soring) exists, though no assurance of future litigation is given.
• Weather/Location: Manufacturing facilities in Florida are exposed to hurricane risks, which could disrupt operations.
• Liquidity: The company has a $1.5 million credit facility with zero balance drawn as of year-end. Management believes cash flows are sufficient for operations and expansion.

Investor Verification Checklist

• OEM Contract Renewals: Verify the status of the Arthrex agreement (terminable Nov 2007 unless extended) and Medtronic contracts, given their combined 33% revenue contribution.
• New Product Commercialization: Confirm the launch dates and initial sales performance of the ICON GI, Bovie Button, and modular laparoscopic instruments, which are critical to the 2007 growth strategy.
• Acquisition Integration: Monitor the financial performance of the new Bovie Canada subsidiary and the realization of projected synergies from the Lican and Henvil acquisitions.
• Inventory Levels: Review inventory days sales outstanding (increased to 109 days in 2006) to ensure no obsolescence issues arise from the buildup of stock for new product lines.
• Debt Covenants: Confirm continued compliance with the bank's fixed charge coverage ratio (1.25:1) under the new credit facility.